VetrixBio today highlighted the strength of its leadership and advisory team, bringing together experience across biotechnology, veterinary medicine, and drug development.
The company is supported by a group of advisors with deep expertise across key disciplines. This includes Professor Duncan Lascelles, a leading authority in small animal surgery and pain management at North Carolina State University; Professor Nicola Mason, a recognized leader in veterinary oncology at the University of Pennsylvania; and Dr. John Marcus, who brings frontline veterinary clinical experience.
The broader advisory group also includes Jon Gold, with experience across public and private company finance; Steve Kirton, founder of an animal health marketing strategy firm; and Errol Taylor, a leader in biopharma intellectual property and patent litigation.
This multidisciplinary foundation supports VetrixBio’s development approach, integrating scientific innovation with a practical understanding of veterinary care and commercialization.
“Building the right team is critical at this stage,” said Graham Lumsden. “We’ve been deliberate in assembling a group that can guide both the science and the path to clinical impact.”
VetrixBio continues to work closely with its advisors as it advances its pipeline in osteoarthritis and cancer, two areas of significant unmet need in companion animal health.
VetrixBio is a biotechnology company focused on developing novel biologic therapies for companion animals. Guided by the belief that pets deserve better medicines, the company is advancing a pipeline targeting osteoarthritis and cancer—two of the most significant unmet needs in veterinary medicine. VetrixBio’s approach centers on translating advances in biologics and immunotherapy into practical treatments designed to improve outcomes and quality of life for dogs and cats. Led by an experienced team spanning biotechnology, animal health, and commercialization, and supported by a network of scientific and clinical advisors, VetrixBio is committed to bringing the next generation of veterinary medicines to market.
VetrixBio, Inc.
47 Enon St., Unit 7, Suite 127
Beverly, MA 01915
info@vetrixbio.com
This press release contains forward-looking statements, including statements regarding the development, potential efficacy, and future progress of VetrixBio’s product candidates. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. VetrixBio undertakes no obligation to update these statements except as required by law.
